HIV Drug Pricing & Pharmaceutical Company News

Drug Pricing: Overview | Drug Pricing: News and Analysis | The Ritonavir (Norvir) Price Increase | Pharmaceutical Company News | Viewpoints

Show Archived (Historical) Articles

Drug Pricing: Overview

The Price Isn't Right (January 25, 2008)
BMS raises HIV/AIDS drug prices, refuses to engage with treatment activists.
In Housing Works AIDS Issues Update, from Housing Works
Shape-Shifting: The Art of Drug Pricing (October 2007)
To read PDF, click here
In Project Inform Perspective, from Project Inform
An Overview of AIDS Drug Access in the United States (May 2004)
Transcript of a talk by Christine Lubinski, Executive Director of the HIV Medicine Association.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Defining the Impact of AIDS Drug Pricing on the Private Sector (May 2004)
Transcript and slides of a talk by Michael Allerton, HIV Operations Policy Coordinator at the Permanente Medical Group.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Defining the Impact of AIDS Drug Pricing on the Public Sector (May 2004)
Transcript and slides of a talk by Lanny Cross, Program Manager of the New York State AIDS Drug Assistance Program.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Research and Development Costs, Unplugged (May 2004)
A chart comparing the R&D costs of five antiretrovirals.
In TAGline, from Treatment Action Group
Untangling the Economics of Drug Pricing (May 2004)
Transcript and slides of a talk by Joshua P. Cohen, a senior research fellow at the Tufts Center for the Study of Drug Development.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Paying for Life: The Issues Behind Drug Pricing (Summer 2003)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Glaxo Will Further Cut Prices of AIDS Drugs to Poor Nations (April 28, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Gilead Offers Tenofovir to Developing Countries at Cost (April 4, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Can We Reform the Drug Industry? (April 2002)
An e-mail discussion between an AIDS activist and a patent attorney.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Patient Care Squeezed by Soaring Drug Prices (April 2002)
An in-depth examination of the drug-pricing war raging in the United States.
In GMHC Treatment Issues, from Gay Men's Health Crisis

Drug Pricing: News & Analysis

Brazil Rejects Patent for Viread (September 5, 2008)
From aidsmap.com
Three HIV Drug Makers Promise More Help to ADAP and HIVers With Private Insurance (August 1, 2008)
To read PDF, click here
From Fair Pricing Coalition
Boehringer, Gilead Freeze Antiretroviral Prices for Some U.S. Agencies (June 5, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Bristol-Myers Slammed By AIDS Group Over Pricing (January 16, 2008)
From Pharmalot
Isentress (Raltegravir) Pricing: Community Sign-On Letter (October 11, 2007)
In AIDS Treatment News, from AIDS Treatment News
Student Global AIDS Campaign Responds to Abbott's Decision to Reduce Price of Kaletra in Low and Middle Income Countries (April 10, 2007)
From Student Global AIDS Campaign
Biotechnology: The Next Frontier for Generic Drugs? (April 7, 2007)
In The New York Times
Optimal Treatment for 40,000 New HIV Cases in U.S. Will Cost $12 Billion Annually, Study Says (November 2, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Free Trade, Expensive Drugs (Fall 2006)
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America
HIV JournalView: The Rise of Generic Antiretrovirals -- In Developed Countries (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
AIDS Activists Cry Foul as Drug Companies Push Prices to Record Levels (July 9, 2005)
To read PDF, click here
From AIDS Treatment Activists Coalition
Medical Innovation Prize Fund: New Idea in Drug Development (June 20, 2005)
A U.S. congressman's plan would allow generic versions of a drug to be sold right after approval.
In AIDS Treatment News, from AIDS Treatment News
Hundreds of U.S. AIDS Groups Demand Freeze on AIDS Drug Prices (October 15, 2004)
Two hundred AIDS organizations sign the letter, which is directed at seven major drug companies.
From AIDS Treatment Activists Coalition
How to Ease the Crisis in Drug Pricing (July 2004)
An analysis of several possible solutions to the trend of escalating drug prices in the United States.
To read PDF, click here
In Project Inform Perspective, from Project Inform
Prominent Medical Group Calls for Full Disclosure on Drug Studies (June 16, 2004)
The American Medical Association proposes a national registry to prevent U.S. pharmaceutical companies from hiding negative clinical trial results.
In Boston Globe
Summary of Highlights From IAPAC Pharmacoeconomics Summit (May 2004)
The one-day summit, held on April 6, 2004, was entitled "Examining the Pharmacoeconomics of U.S. AIDS Drug Access".
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Critics Decry Escalating HIV/AIDS Drug Prices (January 16, 2004)
In The Washington Blade
California Legislature Asks Pension Shareholders to Urge Companies to Make AIDS Drugs Affordable, Available in Developing Countries (August 25, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
GlaxoSmithKline Pressed on AIDS Drug Issue (April 16, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Fighting Back Against Pharmaceutical Company Greed (April 2002)
Some global attempts to lower drug prices might work here in the United States.
In GMHC Treatment Issues, from Gay Men's Health Crisis
PhRMA Speaks! And We All Listen (April 2002)
In GMHC Treatment Issues, from Gay Men's Health Crisis
You Don't Own Me (February 2002)
The terrible consequences of patents -- not on drugs, but on HIV itself.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Drug Pricing (January 25, 2002)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
The Real Cost of Development (July/August 2001)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Who Wants to Be a Millionaire and the Weakest Link (Summer 2001)
Pharmaceutical companies, greed and HIV.
In Women Alive Newsletter, from Women Alive

The Ritonavir (Norvir) Price Increase

Abbott Agrees to Settle Lawsuit Over Norvir Price Hike (August 1, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Glaxo Joins Lawsuit Against Abbott Over Price of Norvir (November 12, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Pharmacies, Drug Wholesaler File Lawsuit Against Abbott Over Norvir Price (October 30, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Wall Street Journal Examines Reason Abbott Increased Price of Antiretroviral Norvir (January 3, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Aetna Files Lawsuit Against Abbott Over 400% Price Increase of Ritonavir (May 27, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
U.S. Government Holds Hearing on Generic Production of Ritonavir (May 26, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Abbott's Norvir Price Hike Is Bad Medicine (May/June 2004)
Bob Huff explains why the December 2003 ritonavir price increase may well doom the development of boosted protease inhibitors.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Cruising With Lazarus: Abbott Laboratories' Pricing Malfunction (May/June 2004)
In Survival News, from AIDS Survival Project
AIDS Advocates, Religious Groups Protest Norvir Price Increase at Abbott Shareholders' Meeting (April 27, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Two HIV-Infected Patients File U.S. Antitrust Suit Against Ritonavir Price Hike (April 20, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Hearing on Drug Reimportation to Include Discussion of Abbott's Pricing of Antiretroviral Norvir (April 14, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation

Viewpoints

Brazil's Threat to Break Antiretroviral Patents Harms Global AIDS Research, Treatment, Chicago Tribune Says (July 6, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Tangle of Interests and Disclosure Omissions Cracks Authors' Case for Early, Aggressive Treatment (January 2005)
AIDS advocate Mike Barr expresses concern over the influence of drug company money on HIV clinical practice -- and over some journals' lax disclosure policies.
In TAGline, from Treatment Action Group
"On the Take" Explores Money, Medicine and Corruption (October 10, 2004)
Former New England Journal of Medicine editor Jerome P. Kassirer's new book deeply criticizes the influence of pharmaceutical industry money on medicine.
In The Boston Globe
Veteran NEJM Editor Takes on Big Pharma as No One Before; Calls for Sweeping Reforms (September 2004)
Dr. Marcia Angell's new book blisteringly critiques the pharmaceutical industry.
In TAGline, from Treatment Action Group
Allow Imported HIV/AIDS Drugs (April 23, 2004)
An op-ed article by Mubarak Dahir, editor of the Express Gay News in Fort Lauderdale, Fla.
In Washington Blade